Urolog. pro Praxi, 2008; 9(3): 109-111

Sceletal metastases in prostate cancer

doc. MUDr. Ladislav Jarolím CSc
Urologická klinika 2. LF UK a FN Motol, Praha

Blocking the prostate cancer cells from interacting with the bone tissue, with the hope of slowing or preventing the development of bone metastases and thereby improving the outcomes, is the aim of treatment options for men with prostate cancer. Multidisciplinary care includes management with pain medications, external radiotherapy, radiopharmaceuticals, surgical treatment, chemotherapy, and bisphosphonates.

Keywords: prostate cancer, bone metastases, skeletal-related events

Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jarolím L. Sceletal metastases in prostate cancer. Urol. praxi. 2008;9(3):109-111.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Berruti A, Dogliotti L, Bitossi R, Fasolis G, Gorzegno G, Bellina M, Torta M, Porpiglia F, Fontana D, Angeli A. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000; 164: 1248-1253. Go to original source... Go to PubMed...
    2. Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PH, Hamdy NA, Landman JO, McCloskey EV, Netelenbos JC, Pauwels EK, Roos JC, Valentijn RM, Zwinderman AH. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 2002; 17: 1057-1064. Go to original source... Go to PubMed...
    3. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ. Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum Pathol 2000; 31: 578-583. Go to original source... Go to PubMed...
    4. Clarke NW. Mechanismus of early prostate cancer metastasis to bone marrow and the influence of lipid maintenance of growth. AAEU 2006.
    5. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003; 95: 1300-1311. Go to original source... Go to PubMed...
    6. Dijstra S, Wiggers T, van Geel BN, Boxma H. Impending and actual pathological fractures in patients with bone metastases of the long bones. A retrospective study of 233 surgically treated fractures. Eur J Surg 1994; 160: 535-542. Go to PubMed...
    7. Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. Český národní webový portál epidemiologie nádorů (online). Masarykova univerzita, (2005), (cit. 2008-2-06). Dostupný z WWW: http://www.svod.cz. Verze 7.0 (2007).
    8. Fourneau I, Broos P. Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures. Acta Chir Belg 1998; 98: 255-260. Go to original source... Go to PubMed...
    9. Groot MT, Boeken Kruger CGG, Pelger RCM, Uyl-de Groot CA. Costs of Prostate Cancer, Metastatic to the Bone, in The Netherlands. Eur Urol 2003; 43: 226-232. Go to original source... Go to PubMed...
    10. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000; 86: 449-452. Go to original source... Go to PubMed...
    11. Hoskin P, Makin W. Oncology for Palliative Medicine New York: Oxford University Press; 2003: 271-289. Go to original source...
    12. Chow E, Wu J, Barnes E. Radiation treatment of bone metastases. In: Singh G, Rubbani S, eds. Bone Metastasis: Experimental and Clinical Therapeutics Totowa, NJ: Humana Press, 2005: 323-336. Go to original source...
    13. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. Cancer J Clin 2007; 57: 43-66.
    14. Joly F, Tannock I. Chemotherapy for patients with hormone-refractory prostate cancer. Ann Oncol 2004; 15: 1582-1584. Go to original source... Go to PubMed...
    15. Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer 2000; 88: 6-14. Go to original source...
    16. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468. Go to original source... Go to PubMed...
    17. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 2005; 96: 964-969. Go to original source... Go to PubMed...
    18. Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging 2003; 20: 175-183. Go to original source... Go to PubMed...
    19. Tannock IF, Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. Go to original source... Go to PubMed...
    20. Vordos D, Paule B, Vacherot F, Allory Y, Salomon L, Hoznek A, Yiou R, Chopin D, Abbou CC, de la Taille A. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer. BJU Int 2004; 94: 524-257. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.